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Introduction
Despite its success in controlling HIV-1 infection and disease 
progression, antiretroviral drug therapy requires a life-long 
commitment and it is still associated with considerable comor-
bidities.1–4 Thus, the development of strategies to completely 
eradicate or to control HIV infection without daily drug intake is 
a priority.1,2,5–10 The report of the “Berlin patient”, cured of HIV 
following hematopoietic stem cell transplant from an individ-
ual homozygous for the ∆32 CCR5 deletion, has raised hope 
in the field.11,12 However, due to the limited chance of finding 
matching ∆32 CCR5 donors and the high risk associated with 
allogeneic stem cell transplantation, recapitulating this clini-
cal success on a large scale appears to be difficult.13,14 In this 
context, gene therapy (GT) represents a viable option, offering 
the possibility to artificially generate ∆CCR5 cells. Different 
GT strategies to edit the CCR5 gene or transcript have been 
tested,15–17 including the use of the CRISPR/Cas9 system18–21 
and the intracellular delivery of transcription activator-like 
effectors nuclease,22–24 or zinc finger nucleases.25–30 The lat-
ter approach is currently being clinically tested (NIH clinical 
trial NCT01543152). Blocking viral entry has the advantage 
of leading to the accumulation of uninfected gene-protected 
cells, thus preventing the continued replenishment of viral 
reservoirs.13,16,31 However, to increase the potency of gene 
therapy approaches and to accomplish long-term control of 
HIV-1 replication, multiple genetic inhibitors interfering with 
different steps of viral replication should be simultaneously 
delivered into target cells.31–34 The multiple targeting GT strat-
egy mimics the antiretroviral drug therapy approach, which 
combines different drugs in order to decrease the chance of 
viral escape. Several genetic HIV inhibitors have been devel-
oped and tested over the years.31,32,35–38 Among these, small 
interfering RNAs (siRNAs) are less immunogenic than pro-
tein-based agents and represent the most potent inhibitory 
effectors, according to preclinical studies.39 Indeed, siRNAs, 
that trigger homology-dependent, post-transcriptional gene 
silencing of their targets, have been used to silence not only 
CCR5,40–44 but also virtually all the HIV-encoded RNAs.45–53 
Moreover, the expression of multiple anti-HIV siRNAs by 
means of self-inactivating (SIN) lentiviral vectors has been 
proven to be effective and safe,53–57 as shown also in human-
ized mouse models35,58,59 and in patients.60,61 Despite these 
achievements, further optimization of these GT approaches 
is required, starting from the selection of new therapeutic 
targets and the design of innovative genetic platforms.61,62 
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Gene therapy holds considerable promise for the functional cure of HIV-1 infection and, in this context, RNA interference (RNAi)-
based approaches represent powerful strategies. Stable expression of small interfering RNAs (siRNAs) targeting HIV genes 
or cellular cofactors has the potential to render HIV-1 susceptible cells resistant to infection. To inhibit different steps of virus 
life cycle, self-inactivating lentiviral vectors expressing multiple siRNAs targeting the CCR5 cellular gene as well as vif and 
tat/rev viral transcripts, under the control of different RNA polymerase III promoters (U6, 7SK, H1) were developed. The use of 
a single RNA polymerase III promoter driving the expression of a sequence giving rise to three siRNAs directed against the 
selected targets (e-shRNA) was also investigated. Luciferase assay and inhibition of HIV-1 replication in human Jurkat T-cell 
line were adopted to select the best combination of promoter/siRNA. The efficacy of selected developed combinatorial vectors 
in interfering with viral replication was evaluated in human primary CD4+ T lymphocytes. We identified two effective anti-HIV 
combinatorial vectors that conferred protection against R5- and X4- tropic viruses. Overall, our results showed that the antiviral 
effect is influenced by different factors, including the promoter used to express the RNAi molecules and the selected cassette 
combination. These findings contribute to gain further insights in the design of RNAi-based gene therapy approaches against 
HIV-1 for clinical application.
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Furthermore, the need of expressing the therapeutic genes 
not only efficiently but also as long as it is required for a life-
long effect are crucial aspects that have not been entirely 
addressed so far.
In this study, we investigated the possibility to combine into 
the same SIN lentiviral vector shRNAs simultaneously target-
ing CCR5 along with three different viral factors (Tat, Rev, 
and Vif) with essential roles in different phases of HIV-1 rep-
lication/pathogenesis. We analyzed: (i) the effect of different 
pol-III promoters (H1, U6, and 7SK) on the shRNAs silencing 
activity, in order to identify the potentially more active combi-
nations; (ii) the possibility to combine two shRNAs with a long 
harpin RNA (lhRNA) within the same vector, in order to obtain 
a platform simultaneously encoding four therapeutic mol-
ecules; (iii) the efficacy of the extended (e)-shRNA strategy 
to target the selected cellular/viral transcripts. The e-shRNA 
strategy is based on the design of an hairpin, optimized in 
length and sequence, that produces three different and active 
siRNAs under the transcriptional control of a single pol-III 
promoter, without inducing the interferon response;63 (iv) the 
silencing/antiviral activity of the developed vectors in different 
experimental settings. Our results brought to light different 
aspects relevant for the design of lentiviral vectors express-
ing multiple anti-HIV-1 siRNAs. Importantly, we also devel-
oped new effective combinatorial strategies that provided 
protection against HIV-1 in human primary CD4+ T lympho-
cytes and that deserve further investigations/improvements.
Results
U6 and H1 represent the best promoters driving the 
expression of different anti-HIV-1 shRNAs within a single 
transcriptional unit
With the aim to combine into the same SIN lentiviral vector 
shRNAs affecting multiple essential steps of HIV-1 replica-
tion/pathogenesis, we selected the cellular CCR5 along with 
the viral tat, rev, and vif as target transcripts. We took advan-
tage of shRNA sequences already tested for their silencing/
antiviral efficacy in different experimental settings. Specifi-
cally, in the case of the tat/rev transcripts, in order to increase 
the efficacy of the strategy, we selected a lhRNA which gives 
rise, once introduced into the cells, to two different siRNAs 
targeting the region common to the two viral transcripts.64 In 
this way, four siRNAs targeting one cellular and three viral 
genes should be produced. The predicted folding and nucleo-
tide sequence of the selected shRNAs are reported in Figure 
1 and in Supplementary Table S1, respectively.
We firstly analyzed the silencing activity of each hairpin 
molecule when expressed under the control of different 
human pol-III promoters by luciferase assay in 293T cells. 
The therapeutic cassette was cloned into the vector upstream 
and in the same orientation of the CMV-EGFP reporter 
gene cassette (Figure 1). Each vector was transfected into 
293T cells along with a reporter plasmid encoding a lucif-
erase gene fused to the respective RNAi target sequence 
 (Supplementary Figure S1). Measurement of luciferase 
activity provided a readout of vector silencing efficacy, with 
the most effective vectors resulting in a higher suppression 
of luciferase activity. The H1 promoter was overall the best 
performing promoter (Figure 2a–c) and the only one leading 
to a noteworthy suppression in the case of the vif-specific 
shRNA (40.8 ± 1.7% of inhibition) (Figure 2b). To assess the 
impact of orientation on shRNA efficacy, the H1lhtat/rev cas-
sette was also inserted in the opposite orientation with no sig-
nificant impact on the silencing activity (Figure 2c). To further 
confirm these data, we evaluated the activity of the shCCR5 
by investigating the knockdown of endogenous CCR5 in 
human primary macrophages. CCR5 downregulation was 
observed when cells were transduced with the shCCR5 vec-
tors, being the U6 and the H1 the best performing promoters, 
in agreement with the luciferase assay (Donor 1, Figure 2d 
and Supplementary Figure S2). These data were confirmed 
with Donor 2-derived macrophages.
Design and evaluation of different combinatorial anti-
HIV-1 vectors
As a next step, to simultaneously express the selected shR-
NAs, each therapeutic molecule driven by the most efficient 
promoter, as resulted with the luciferase knockdown assay, 
was combined generating the U6shCCR5-H1lhtat/rev-H1sh-
vif vector. Moreover, additional combinatorial vectors were 
designed. In the U6shCCR5-H1lhtat/rev-7SKshvif vector, the 
shCCR5 and the lhtat/rev were maintained under the control 
of the U6 and the H1 promoters, respectively, while the 7SK 
promoter was adopted to express the vif-specific shRNA. In 
the U6shCCR5-7SKshvif-H1lhtat/rev vector, the H1lhtat/rev 
and the 7SKshvif cassettes were swapped, as compared to 
the above-described vector, in order to assess the impact 
of cassette position on vector antiviral activity. Finally, the 
7SKshCCR5-U6lhtat/rev-H1shvif vector was also generated 
(Figure 3a).
The efficacy of the developed vectors was evaluated by 
luciferase assay. The results show that the CCR5-, the vif- 
and the tat/rev-specific shRNAs, when expressed in the 
context of a triple cassette vector, maintained the expected 
silencing activity in all the tested conditions, irrespectively of 
either the employed promoter or the cassette position (Fig-
ure 3b,c).
To further exploit combinatorial anti-HIV-1 vectors, we 
developed an e-shRNA that allows the expression of three 
siRNAs directed against the selected transcripts under the 
control of a single pol-III promoter. The hairpin stem length 
is a critical parameter for proper processing and optimal 
activity of the siRNAs produced by the e-shRNA. Moreover, 
G:U wobble pairings were inserted at regular intervals in the 
sense strand of the e-shRNA, to attenuate the innate immune 
response to long dsRNAs63
 (Figure 4a). In the luciferase 
assay, under all the tested conditions, silencing activity was 
achieved only when the e-shRNA was expressed by the H1 
promoter (Figure 4b,c).
Inhibition of HIV-1 replication in CD4+ T lymphoblastoid 
cells and in human primary CD4+ T cells transduced with 
the combinatorial antiviral vectors
To address the antiviral activity of the combinatorial vectors, 
CD4+ T lymphoblastoid Jurkat cells were transduced with 
recombinant lentiviral particles. Vector titers typically ranged 
from 106 to 107 transducing units (TU)/ml ( Supplementary 
Figure S3a) and a multiplicity of infection (MOI) of 1 
TU/cell was used, obtaining the % of enhanced green 
www.moleculartherapy.org/mtna
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fluorescent protein-positive (EGFP+) Jurkat cells reported 
in  Supplementary Figure S3b,c. Once assessed that cells 
could be efficiently transduced without effect on cell viability 
(data not shown), transduced Jurkat cells were infected with 
the HIV-1 HXBc2 Vpr+/Vpu+/Nef+ strain (MOI = 0.1 TCID50/
cell). Viral inhibition was assessed by measuring reverse 
transcriptase (RT) activity in the culture supernatants at dif-
ferent time points postinfection. Effective reduction of HIV-1 
replication was achieved with both the U6shCCR5-7SKshvif-
H1lhtat/rev and the U6shCCR5-H1lhtat/rev-7SKshvif triple 
cassette vectors  (Figure 5a). The former vector almost com-
pletely suppressed viral replication up to 10 days after infec-
tion, while the latter determined a 10-fold decrease in virus 
production. On the contrary, both the U6shCCR5-H1lhtat/
rev-H1shvif and the 7SKshCCR5-U6lhtat/rev-H1shvif vectors 
did not confer protection against HIV-1 infection. Among the 
e-shRNA-encoding vectors, the H1-driven hairpin provided 
strong inhibition of viral replication up to 10 days postinfec-
tion. According to the results obtained with the luciferase 
assay, neither the U6- nor the 7SK-driven e-shRNA displayed 
antiviral activity (Figure 5b). Thus, U6shCCR5-7SKshvif-
H1lhtat/rev and the H1e-shRNA were identified as the most 
effective anti-HIV-1 combinatorial vectors among the ones 
developed. Therefore, the antiviral activity of these vectors 
was investigated in a more physiologically relevant setting. To 
this end, human primary CD4+ T lymphocytes were purified 
from buffy coats of three healthy donors and transduced with 
the selected vectors. The transduction efficiency measured 
as percentage of EGFP-positive cells ranged from 15 to 30% 
(Supplementary Figure S4). To obtain an almost pure pop-
ulation of transduced cells, 4 days after transduction, lym-
phocytes were fluorescence-activated cell sorting (FACS) 
Figure 1  Schematic representation of vectors expressing single anti-HIV-1 hairpin RNAs. Third-generation self-inactivating lentiviral 
vector backbone pLL3.7 that was used to derive the antiviral constructs. The selected shRNA was inserted upstream of the CMV-EGFP 
cassette under the control of either the U6, the 7SK, or the H1 human pol-III promoter. Arrows indicate the transcriptional orientation of the 
RNAi trigger cassette. Each hairpin molecule encompasses complementary passenger and guide strands separated by a 9 nt loop, followed 
by the pol-III termination signal (poly-T).82 The predicted folding of each shRNA is shown, as calculated by the mfold web server (version 3.5)83 
with default parameters at 37 °C. The thermodynamic stability (∆G) is also reported in Kcal/mol. The shCCR5 and the shvif molecules give rise 
to a single siRNA against the cellular CCR5 and the HIV-1 vif transcript, respectively. The lhtat/rev leads to the generation of two siRNA both 
targeting the first overlapping exon of the tat and rev viral genes. The shRNA control encodes for a scrambled sequence.
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sorted on the basis of EGFP expression. Twenty-four hours 
later, once assessed that the expression of multiple siRNAs 
did not affect cell viability as compared to control cells (data 
not shown), 2.5 × 106 (Donor 3) and 1 × 106 (Donors 4 and 5) 
cells were challenged with equivalent RT units (10,000 cpm) 
of either the CXCR4 coreceptor-using HIV-1 HXBc2 Vpr+/
Vpu+/Nef+ or the CCR5 coreceptor-using HIV-1 NL4-3-ADA. 
Infected cells were maintained in 10% fetal bovine serum 
(FBS) Roswell Park Memorial Institute (RPMI) containing 
IL-2. The RT activity in culture supernatants was measured 
at different time points after infection.
In the case of Donor 3, both the U6shCCR5-7SKshvif-H1lhtat/
rev and the H1e-shRNA vector induced a striking inhibition of 
viral replication up to 12 days postinfection, when challenged 
with both HIV-1 strains (Figure 6). Inhibition was also detected 
in the case of Donors 4 and 5, although to a less extent, likely 
reflecting the effect of the different cellular density employed 
compared to the one adopted for Donor 3. Moreover, in the case 
of the R5 virus, especially for Donor 4, the triple cassette vec-
tor displayed, overall, the most potent antiviral effect (Figure 6).
Discussion
Supported by the success of the “Berlin patient”, over the last 
years, several gene therapy approaches have been devel-
oped to treat HIV-1 infection. As for chemotherapy regimens 
used in the current clinical practice, a combination of multiple 
antiviral reagents should be adopted. The strategies adopted 
so far, despite encouraging results, suffer of different prob-
lems that should be further addressed.
Figure 2 Silencing activity of the different single shRNA-expressing vectors. (a–c) The shCCR5-, the shvif-, or the lhtat/rev-expressing 
vector containing the indicated promoter was cotransfected along with its respective reporter plasmid into 293T cells and luciferase activities 
were measured 48 hours later. To correct for transfection efficiency, relative luciferase activities were calculated from the ratio between Renilla 
and background firefly luciferase activities. The indicated percentages represent the relative luciferase activity calculated by setting at 100% 
the value obtained from cells transfected with the corresponding scrambled vector. Black bars refer to vectors harboring the RNAi trigger 
cassette in the same orientation as the CMV-EGFP reporter cassette, while the gray bar in panel (c) refers to the vector containing the H1lhtat/
rev cassette in the opposite orientation. The mean and standard deviation from three replicated experiments are presented (*P < 0.05; **P < 
0.01; ***P < 0.001; t-test, relative to the corresponding scrambled). (d) Monocyte-derived macrophages were transduced twice with vectors 
expressing the shCCR5 or the scrambled sequence under the control of the U6, the 7SK, or the H1 promoter. The cells were harvested 3 
days after the second transduction and analyzed by FACS with anti-human CCR5 antibody staining. The indicated percentages represent the 
reduction of CCR5-positive cells calculated with respect to the values obtained for the scrambled vector-transduced cells. Results from two 
representative Donors (1 and 2) are shown.
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Here, we generated different combinatorial vectors based 
on a self-inactivating HIV-1 platform expressing multiple shR-
NAs targeting both cellular and viral transcripts. Combinato-
rial RNAi (co-RNAi) can be achieved by inserting multiple 
pol-III promoter/shRNA cassettes within the same vector45 or 
by expressing a single sequence that, once introduced into 
the cells, gives rise to more than one siRNA (e-shRNA).63 In 
this study, we directly compared both these strategies. Spe-
cifically, we combined in a single construct shRNAs targeting 
different steps of HIV-1 life cycle (entry, transcription, nuclear 
export of viral RNAs, and production of infectious particles). 
In particular, CCR5, tat, rev, and vif were selected as tar-
get transcripts. Of note, taking into account that the selected 
tat/rev target sequence is also present in additional viral 
transcripts (unspliced and single-spliced), additional silenc-
ing activity cannot be excluded. Furthermore, vectors were 
designed to minimize viral escape not only by targeting mul-
tiple genes at the same time, but also by (i) employing an 
shRNA active against a cellular gene, CCR5, which is char-
acterized by a low mutation rate and (ii) selecting viral tar-
get sequences which have been already shown to be highly 
conserved among different clades.64,65 Indeed, since the aim 
of our study was to compare the antiviral efficacy of different 
co-RNAi strategies, we selected shRNAs that were already 
described for their antiviral activity along with well character-
ized pol-III promoters (i.e., U6, H1, and 7SK). Moreover, we 
Figure 3 Inhibition of reporter gene expression by combination of multiple anti-HIV-1 shRNAs. (a) The triple cassette vectors express 
the shCCR5, the shvif and the lhtat/rev as independent transcriptional units, according to different combinations of promoter-RNAi trigger. 
Each vector encoding the triple combination of antiviral cassettes driven by the U6, the 7SK, or the H1 promoter was cotransfected along 
with one (b) (CCR5, vif, or tat/rev) or all (c) (CCR5 + vif + tat/rev) luciferase reporter plasmids into 293T cells and luciferase activities 
were measured 48 hours later. The indicated percentages refer to the relative luciferase activity calculated as reported above. The average 
values from three independent experiments, with standard deviations, are given (*P < 0.05; **P < 0.01; ***P < 0.001; t-test, relative to the 
corresponding scrambled control depending on the promoter driving the shRNAs).
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also combined for the first time two shRNAs (CCR5- and vif- 
specific) with an lhRNA (tat/rev) obtaining lentiviral vectors 
simultaneously expressing four siRNAs.
Firstly, we analyzed the impact of the pol-III promoter on the 
shRNA silencing activity. We show that, when the therapeutic 
RNA is targeting a viral transcript, the choice of the promoter 
might be relevant, while its orientation does not seem to have 
a major impact. Of note, we cannot exclude, at the moment, 
that the cassette orientation might have an impact on the titer 
of the recombinant particles, an aspect that is worth to be fur-
ther investigated. In particular, the H1 is the best promoter in 
the case of the tat/rev-specific lhRNA and the only one lead-
ing to a noteworthy silencing of the vif transcript. It is worth 
mentioning that a 40.8 ± 1.7% of inhibition in the luciferase 
Figure 4 Inhibition of reporter gene expression by anti-HIV-1 e-shRNAs. (a) Schematic representation of lentiviral vectors expressing the 
e-shRNA is displayed. The e-shRNA produces three siRNAs against the CCR5, the tat/rev and the vif transcripts, from the stem base to the 
loop region of the hairpin, respectively, under the control of a single promoter (U6, 7SK, H1). The predicted folding of e-shRNA is shown, as 
calculated by the mfold web server (version 3.5)83 with default parameters at 37 °C. The thermodynamic stability (∆G) is also reported in Kcal/
mol. G:U pairings are indicated with a black arrowhead. Each vector encoding the e-shRNAs driven by the U6, the 7SK, or the H1 promoter 
was cotransfected along with one (b) (CCR5, vif or tat/rev#) or all (c) (CCR5 + vif + tat/rev#) luciferase reporter plasmids into 293T cells and 
luciferase activities were measured 48 hours later. The indicated percentages refer to the relative luciferase activity calculated as reported 
above. The average values from three independent experiments, with standard deviations, are given (*P < 0.05; **P < 0.01; ***P < 0.001; 
t-test, relative to the corresponding scrambled control depending on the promoter driving the shRNAs); tat/rev#: luciferase reporter plasmid 
containing the target sequence of the siRNA against the tat/rev gene produced by the e-shRNA.
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assay is not expected to necessarily correlate with a lack of 
biological effect of the selected vif-specific shRNA especially 
in vivo where Vif plays a crucial role.66–70 Finally, the CCR5-
specific shRNA showed a potent silencing activity indepen-
dently from the pol-III promoter employed.
Next, we tested the impact of the combinatorial vector 
design on antiviral activity. Since our first aim was to inves-
tigate whether a platform expressing multiple siRNAs under 
the transcriptional control of different pol-III promoters within 
a SIN vector was stable and efficient in transducing HIV-1 tar-
get cells, we selected Jurkat lymphoblastoid T cells as exper-
imental system. This cell line, being target of CXCR4-using 
HIV-1 strains, offered us the possibility to identify, among 
the generated vectors, the ones able to efficiently reduce 
viral replication despite the effect of the potent shCCR5. 
This aspect was crucial in order to select the best shRNA-
based strategy active on viruses regardless their tropism, as, 
given the essential role of CXCR4 in vivo, only CCR5 can 
be target of silencing. All the developed combinatorial vec-
tors were able to transduce Jurkat cells, as analyzed in terms 
of EGFP-positive cells. Specifically, the U6shCCR5-H1lhtat/
rev-H1shvif vector was expected to be the most potent with 
respect to antiviral activity, being characterized by the com-
bination of the different shRNAs cloned under the transcrip-
tional control of the best performing promoter. Even though 
efficient in silencing all the target transcripts in the luciferase 
assay, when the U6shCCR5-H1lhtat/rev-H1shvif vector was 
adopted to transduce Jurkat T cells, HIV-1 replication was not 
inhibited. This result could be explained by the presence of 
two H1 promoters within the vector that might lead to recom-
bination events upon transduction, with deletions of one or 
more therapeutic cassettes, as already reported.57,71 On the 
other hand, a lentiviral vector expressing multiple shRNAs 
under the control of repeated pol-III promoters conferred 
strong resistance to HIV-1 infection in transduced CD34+ 
progenitor cells65 and it has been adopted in early-phase 
clinical trial.60 Thus, we cannot exclude that the inserted 
pol-III/shRNA combination per se, independently from the 
presence of repeated H1 sequences, might influence vector 
stability with detrimental effects on the vector antiviral activ-
ity. In agreement with this hypothesis, also the 7SKshCCR5-
U6lhtat/rev-H1shvif vector, which lacks shRNA expression 
Figure 5 Inhibition of HIV-1 replication in Jurkat T cells expressing multiple siRNAs against the CCR5, the vif and the tat/rev targets. 
(a,b) Jurkat T cells transduced with the triple cassette vectors, the e-shRNA expressing vectors or the control empty and scrambled vectors 
were infected with the HIV-1 HXBc2 Vpr+/Vpu+/Nef+ R4-tropic molecular clone (multiplicity of infection = 0.1 TCID50/cell). Culture supernatants 
were collected at the indicated time points and assayed for RT activity. The reported results have been replicated in at least three independent 
experiments. The scrambled control plotted in the graphs represents the U6-scrambled vector. Comparable results were obtained with the 
7SK- and the H1-scrambled vectors (data not shown).
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from repeated promoters, did not protect Jurkat cells from 
HIV-1 challenge. Of note, the cassette array within this vec-
tor, that represents the best combination of pol-III/shRNA in 
terms of silencing activity without promoter repetition, is the 
only one with the 7SK positioned as first. Interestingly, both 
U6shCCR5-H1lhtat/rev-H1shvif and 7SKshCCR5-U6lhtat/
rev-H1shvif were consistently characterized by a titer at least 
1 log lower than the one obtained for the U6shCCR5-H1lhtat/
rev-7SKshvif and U6shCCR5-7SKshvif-H1lhtat/rev vectors. 
Furthermore, even though target cells were transduced with 
the same number of TU, the percentages of EGFP-positive 
cells obtained with U6shCCR5-H1lhtat/rev-H1shvif and 
7SKshCCR5-U6lhtat/rev-H1shvif were constantly lower than 
the ones obtained in the case of the U6shCCR5-H1lhtat/
rev-7SKshvif and U6shCCR5-7SKshvif-H1lhtat/rev vectors 
(Supplementary Figure S3). On the other hand, these two 
latest vectors efficiently controlled viral replication up to 10 
days postinfection in HIV-1 challenged Jurkat cells. Interest-
ingly, in both cases, the lhtat/rev was under the transcriptional 
control of the H1 promoter. Since in the adopted experimental 
setting the silencing activity of CCR5 and vif transcripts can-
not be appreciated and taking into account that in the lucifer-
ase assay the H1lhtat/rev silenced its targets regardless its 
position with respect to the 7SKshvif cassette, this result also 
suggests that the U6shCCR5-7SKshvif-H1lhtat/rev and the 
U6shCCR5-H1lhtat/rev-7SKshvif are the more stable cas-
sette arrays conferring to the vectors the best performance 
upon transduction. Furthermore, the pol-III/shRNA combina-
tion more than the position of the single cassette with respect 
to each other seems to be the critical aspect. Indeed, the 
swap between the 7SKshvif and the H1lhtat/rev does not 
have a major impact on their antiviral activity.
In the case of the e-shRNA-expressing vectors, the 
sequences generating the siRNAs were positioned across 
the span of the duplex with the siRNA against CCR5 as first, 
followed by the siRNAs targeting the tat/rev and the vif tran-
scripts. The results obtained with both the luciferase assay 
and the viral challenge of transduced Jurkat T cells indicated 
that H1 was the only effective promoter in driving the produc-
tion of active siRNAs. Overall, our data clearly indicate that, 
in the case of the e-shRNA, the silencing activity is strongly 
influenced by the selected pol-III promoter. To our knowledge, 
this is the first report directly correlating the impact of different 
promoters on e-shRNA efficacy. Furthermore, by comparing 
the results obtained with the two co-RNAi strategies, we can 
conclude that, in the case of multiple cassette constructs, 
the design of the vector both in terms of promoter/shRNA 
cassette selection and its positioning has an impact on its 
performance upon transduction and thus cannot rely only on 
luciferase assay. By contrast, in the case of the e-shRNA-
expressing vectors, the pol-III promoter appears to be the 
critical aspect and the luciferase assay might be sufficient to 
select the best performing platform.
The most promising triple and e-shRNA vectors were fur-
ther validated in human primary CD4+
 T lymphocytes chal-
lenged with the CXCR4 coreceptor-using HIV-1 HXBc2 Vpr+/
Vpu+/Nef+ and the CCR5 coreceptor-using HIV-1 NL4-3-ADA. 
Consistent with previous data obtained with the lymphoblas-
toid T cell line, the triple vector showed on average a higher 
HIV-1 inhibition than the e-shRNA vector over the 12-day 
time course of infection. This is not surprising also consider-
ing that the multiple-cassette vector encodes four siRNAs, 
two of which active against tat/rev. Overall, no significant dif-
ferences in terms of inhibition could be appreciated between 
the CXCR4 and CCR5 coreceptor-using HIV-1 strains. This 
result might be simply explained by the fact that also in the 
primary cells we employed, the major contribution in terms 
of antiviral activity is likely due to the silencing of viral tran-
scripts targeted by the tat/rev-specific siRNAs. The contri-
bution of CCR5- and vif-specific shRNAs is currently under 
investigation.
The first lentiviral vector expressing a triple combination 
of shRNAs targeting viral transcripts is approaching clinical 
application.58 Our study on the one hand demonstrates that it 
is feasible to further increase the genetic barrier to viral resis-
tance by including in a single vector sequences expressing 
Figure 6 Inhibition of HIV-1 replication in human primary CD4+ T lymphocytes transduced with the combinatorial vectors. CD4+ T cells 
were transduced with either the empty vector, the H1e-shRNA or the U6shCCR5-7SKshvif-H1lhtat/rev vector. Four days post-transduction, 
enhanced green fluorescent protein (EGFP)-expressing cells were sorted by FACS and infected with the CXCR4 coreceptor-using HIV-1 
HXBc2 Vpr+/Vpu+/Nef+ or the CCR5 coreceptor-using HIV-1 NL4-3-ADA. Culture supernatants were harvested at the indicated time points 
postinfection and tested for reverse transcriptase (RT) activity. The indicated percentages represent the reduction of the relative RT activity 
calculated with respect to the value obtained for the empty vector-EGFP-positive selected-transduced cells.
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four siRNAs targeting one essential cellular and three crucial 
viral genes. On the other hand, it highlights some important 
strengths and pitfalls of different platforms/tools used for the 
design and testing of multiple shRNAs delivery systems, pro-
viding valuable insights for the development of an improved 
reliable combinatorial RNAi-based approach against HIV-1.
Materials and methods
Cell lines and cell cultures. Human embryonic kidney 293T 
cells were grown in Dulbecco’s modified Eagle’s medium 
(Gibco, Life Technologies, Monza, Italy) supplemented with 
10% heat-inactivated FBS (Gibco, Life Technologies). Human 
T lymphoblastoid Jurkat cells (Clone E6-1) were maintained 
in Roswell Park Memorial Institute’s 1640 medium (RPMI) 
(Gibco, Life Technologies) supplemented with 10% FBS. 
Human primary monocytes were isolated by plastic adher-
ence from buffy coats of healthy blood donors after Ficoll-
Paque PLUS (GE Healthcare, Milan, Italy) purification. 
Monocytes were cultured in RPMI containing 10% FBS 
and macrophage colony-stimulating factor (M-CSF) (500 U/
ml) (Miltenyi Biotec, Calderara di Reno, Bologna, Italy) for 
7 days to differentiate into macrophages. Preparation purity 
was evaluated by measuring the percentage of CD14+ cells 
through FACS analysis. The cut-off employed to accept the 
purity of monocyte-derived macrophage preparation was a 
CD14+ percentage higher than 90%. Human primary CD4+ 
T lymphocytes were purified from buffy coats by Rosette 
Sep (StemCell Technologies, Peschiera Borromeo, Milan, 
Italy), according to the manufacturer’s instructions. The purity 
of the CD4+ T cell population ranged from 95 to 100%, as 
estimated by FACS analysis, as follows. 5 × 105 cells were 
stained with monoclonal antibodies to human CCR5 (APC 
Mouse Anti-Human CD195, BD Biosciences, Milan, Italy), 
CD4 (PE-Cy7 mouse anti-human CD4, BD Biosciences), 
CD14 (CD14-PE, human, Miltenyi Biotec), CD8 (anti-human 
CD8a APC, eBioscience, Prodotti Gianni, Milan, Italy) or 
CD19 (CD19-FITC, human, Miltenyi Biotec), according to the 
manufacturer’s instructions. The cells were also stained with 
isotype controls for each of the specific antibodies, as well 
as with the 7-Amino-Actinomycin D (7-AAD) viability dye (BD 
Biosciences). CCR5 expression level from two representa-
tive donors is reported in Supplementary Figure S5. When 
required, cells were incubated with FcR blocking reagent 
(Miltenyi Biotec) before staining. Samples were acquired on 
a LSRII (BD Biosciences) instrument and the data analysis 
was performed with FlowJo (Tree Star, Ashland, OR) soft-
ware. CD4+ T cells were cultured in RPMI medium supple-
mented with 10% FBS, penicillin (100 U/ml), streptomycin 
(100 µg/ml) and stimulated with phytohemagglutinin (10 µg/
ml) (Sigma-Aldrich, Milan, Italy) for 2 days. Cells were subse-
quently cultured without phytohemagglutinin.
Construction of multifunctional self-inactivating lentiviral 
vectors.  The human U6 promoter was amplified from 293T 
genomic DNA with primers 5′-AAGGTCGGGCAGGAAGA 
GGGCCTA-3′ and 5′-GCACGGTGTTTCGTCCTTTCCACA-3′  
(GenBank: X07425.1, nt 1–269). The human 7SK promoter 
was amplified from HeLa genomic DNA with primers 5′-CTG 
CAGTATTTAGCATGCCCCACC-3′ and 5′-CCGAGGTACCCA 
GGCGGCGCACAA-3′ (GenBank: X05490.1, nt 1–246). The 
EcoRI and MluI sites were included at the 5′ and 3′ end, 
respectively, of both promoters. The human H1 promoter was 
derived from the pLVTHM vector,72 after digestion with EcoRI 
and MluI.
To obtain the shCCR5,42 the shvif47 and the scrambled 
sequence,42 two complementary DNA oligonucleotides 
flanked by MluI and ClaI sites were synthesized, annealed, 
and inserted at the EcoRV site of the pBluescript II KS plas-
mid (Stratagene, Agilent Technologies, Cernusco sul Naviglio 
Milan, Italy).
To generate the lhtat/rev64 and the e-shRNA sequences, 
a two-step polymerase chain reaction (PCR) approach was 
used, as described elsewhere.73 Briefly, the first PCR reac-
tion was performed using a plasmid containing the human 
U6 promoter and 153 nt of the downstream snU6 RNA gene 
as template. The U6 forward primer described above and a 
reverse primer complementary to the last 14 nt of the snU6 
RNA gene, followed by sequences complementary to the 
sense strand and the 9 nt loop of the hairpin were employed 
(lhtat/rev reverse primer 1: 5′-TCTCTTGAAGAGAAACTTG 
ATAAGTCTAACTGTTCTAATGAACTCTTCATCGCTATCTCC 
GCACGCGTAAACAGAAAAACAA-3′; e-shRNA reverse primer 
1: 5′-TCTCTTGAAGGGATGTATACTTCTAAACATACTCCACT 
TCTTCCTACCATGTGGGTATAAACTAAGCTTACTCACGCGT 
AAACAGAAAAACAA-3′). An MluI site (underlined) was 
inserted between the end of the snU6 RNA gene and the first 
nucleotide of the hairpin, to facilitate subsequent cloning. The 
PCR reaction was carried out as follows: 1 minute at 94 °C, 
1 minute at 55 °C, and 1 minute at 72 °C for 30 cycles. 
A second PCR step was performed employing the same U6 
forward primer and a reverse primer harboring sequences 
complementary to the 9 nt loop, followed by the antisense 
strand of the hairpin, the pol-III terminator sequence and the 
ClaI site (lhtat/rev reverse primer 2: 5′-ATCGATAAAAAGCGG 
AGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTC 
ATCAAGCTTCTCTCTCTTGAA-3′; e-shRNA reverse primer 2: 
5′-ATCGATAAAAAGAGCAAGCTCAGTTTACACCCACATGG 
CAGGAAGAAGCGGAGTATGTTCAGAAGTACACAT 
CCCTCTCTTGAAA-3′). The PCR to obtain the lhtat/rev 
was carried out as described above, while amplification to 
obtain the e-shRNA was performed as follows: 40 seconds 
at 98 °C, 1 minute at 55 °C, and 1 minute at 72 °C for 30 
cycles. The resulting PCR products include the U6 promoter 
and a fragment of the downstream snU6 RNA gene, fol-
lowed by the MluI site, the sense and the antisense hairpin 
sequences of either the lhtat/rev64 or the e-shRNA (5′-GAGT 
AAGCTTAGTTTATACCCACATGGTAGGAAGAAGTGGAGT 
ATGTTTAGAAGTATACATCCCTTCAAGAGAGGGATGTGT 
ACTTCTGAACATACTCCGCTTCTTCCTGCCATGTGGGTG 
TAAACTGAGCTTGCTCTTTTT-3′) separated by the 9 nt loop, 
the pol-III terminator signal and the ClaI site. These fragments 
were ligated into the EcoRV-linearized pBluescript II KS plas-
mid. Of note, in the e-shRNA, the siRNA against the tat and 
rev genes has a different target sequence with respect to the 
ones produced by the lhtat/rev. Indeed, considering that the 
stem region of the extended hairpin should not exceed 66 bp 
in length for effective production of multiple and functional 
siRNAs, the lhtat/rev guide strand sequence was replaced 
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with a shorter one, generating one single siRNA that targets 
a distinct region of the tat/rev common transcript.63 The U6 
promoter was then replaced by either the 7SK or the H1 pro-
moter by enzymatic digestion. To obtain the siRNA-encoding 
cassettes, the U6, the 7SK, or the H1 promoter was inserted 
into the pBluescript II KS plasmid immediately upstream of 
the siRNA, between the EcoRI and the MluI sites.
The third-generation pLentiLox3.7 (pLL3.7) self-inactivat-
ing lentiviral vector,74 which contains an EGFP reporter gene 
and served as the control empty vector, was used to develop 
the anti-HIV-1 constructs. To obtain vectors expressing one 
single hairpin molecule, the shRNA, lhtat/rev or e-shRNA 
transcriptional unit was subcloned into the pLL3.7 plasmid 
between the XbaI and XhoI sites. Vectors expressing three 
hairpin molecules were constructed starting from the pBlue-
script II KS plasmid containing one single hairpin cassette. 
Initially, the plasmid encoding the first cassette was ClaI 
digested and protruding ends were filled-in by the Klenow 
fragment of the DNA polymerase. The linearized plasmid 
was SalI digested in order to allow the subsequent ligation 
to the second cassette, encompassed within a SmaI-SalI 
fragment derived from the relative pBluescript II KS plasmid. 
The resulting construct, encoding two out of the three hairpin 
cassettes, was linearized by SalI digestion and cut with XhoI, 
after treatment with the Klenow enzyme. Next, the third cas-
sette was inserted with the XhoI-SmaI restriction sites. Finally, 
the fragment containing the triple cassette was excised with 
XbaI-XhoI and inserted into the pLL3.7 backbone.
Luciferase assay. Reporter plasmids were obtained, each 
encoding the shCCR5, the shvif or the lhtat/rev target 
sequence downstream of the Renilla luciferase open reading 
frame, followed by the firefly luciferase gene, to control for cell 
viability and transfection efficiency. Plasmids were constructed 
by directed insertion of the RNAi target region into the XhoI-
NotI sites of the psiCheck2 plasmid (Promega, Milan, Italy), 
downstream of the Renilla luciferase gene (Supplementary 
Figure S1). Target fragments were obtained by annealing two 
complementary DNA oligonucleotides flanked by XhoI and 
NotI sites. Sequences of the forward oligonucleotide were as 
follows: shCCR5 target 5′-CAAGAGGCTCCCGAGCGAG-
CAAGCTCAGTTTACACCCGATCCACTGGGGAGCA-3′ 
(GenBank:X91492.1, nt 1224–1276); shvif target 5′-CCCTC 
ATCCAAGAATAAGTTCAGAAGTACACATCCCACT 
AGGGGATGCTAGATTG-3′ (B.FR.83.HXB2, nt 5178–5232); 
lhtat/rev target 5′-GCGGAGACAGCGACGAAGAGCTCATC 
AGAACAGTCAGACTCATCAAGCTTCTC-3′ (B.FR.83.HXB2, 
nt 5983–6035); e-shRNA-derived tat/rev target 5′-CCTTAGG 
CATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACG 
AAGAGCT-3′ (B.FR.83.HXB2, nt 5955–6004).
For luciferase assays, 293T cells were plated in 96-well 
plates at a density of 1 × 104 cells/well in 100 µl of Dulbec-
co’s modified Eagle’s medium 10% FBS. The next day, cells 
were cotransfected with 50 ng of the psiCheck2-derived 
plasmid(s) and 300 ng of the siRNA-expressing vector, using 
Lipofectamine 2000 reagent (Invitrogen, Life Technologies, 
Monza, Italy), as suggested by the manufacturer. Two days 
post-transfection, firefly and Renilla luciferase activities were 
assessed using the Dual Glo Luciferase Assay System (Pro-
mega), according to the manufacturer’s instructions. Relative 
luciferase activities were calculated from the ratio between 
Renilla and background firefly luciferase activities. Rela-
tive activity for the control vector encoding the scrambled 
sequence was set to 100% and activities for the correspond-
ing samples calculated accordingly.
Vector production and transduction of target cells.  Vesicu-
lar stomatitis virus (VSV)-G pseudotyped vector stocks were 
produced by calcium phosphate transfection of 293T cells. 
Briefly, 2.5 × 106 cells were seeded on 10 cm Petri dishes and, 
when subconfluent, cotransfected with 15 µg of the appropri-
ate gene transfer vector, 5 µg of pMDL, 3 µg of pCMV-Rev 
and 1.5 µg of pCMV-VSV-G (kindly provided by T. Friedman, 
University of California, San Diego, CA). The culture superna-
tants were collected on day 2 post-transfection, filtered with a 
0.45-µm-pore-size membrane and stored at −80 °C until use. 
When required, vector particles in the supernatants were 
concentrated by ultracentrifugation (27,000 rpm, 2 hours, 4 
°C). Infectious titer was determined by transducing 293T cells 
with serial dilutions of the lentiviral stocks, and 72 hours later 
EGFP expression was assessed by flow cytometry.
Monocyte-derived macrophages (1 × 106) were transduced 
with lentiviral vectors for 8 hours over 2 consecutive days at 
a MOI of 1 TU/cell in RPMI containing 10% FBS. After trans-
duction, macrophages were maintained in culture medium 
supplemented with M-CSF (500 U/ml) for 3 days and ana-
lyzed by FACS for CCR5 surface expression. Jurkat cells 
(1 × 106) were incubated with vectors at an MOI of 1 TU/cell 
in RPMI 10% FBS. After 3 days of culture, the transduction 
efficiency was ascertained on the basis of EGFP expres-
sion. CD4+ T lymphocytes (1 × 106) were spin-infected with 
lentiviral vectors (1,200 rpm, 2 hours, 25 °C) at an MOI of 
0.5 TU/cell in RPMI supplemented with 10% FBS and poly-
brene (8 µg/ml). After transduction, fresh culture medium 
containing penicillin (100 U/ml), streptomycin (100 µg/ml), 
and IL-2 (100 U/ml) (R&D Systems, Space Import-Export, 
Milan, Italy) was added to the cells. Four days post-transduc-
tion, homogeneous EGFP+ populations were obtained by flow 
cytometric sorting and used for the next experiments.
HIV-1 stock production and infection. HIV-1 HXBc2 Vpr+/Vpu+/
Nef+ was produced by transfection of 5 × 106 Jurkat cells with 
10 µg of the pSVC Vpr+/Vpu+/Nef+ construct (kindly provided 
by Heinrich Göttlinger, University of Massachusetts Medi-
cal School, Massachusetts) by the DEAE-dextran method, 
as previously described.75 This plasmid is a derivative of the 
pSVC21 construct,76 containing the HIV-1 HXBc2 molecular 
clone,77 where the vpr, vpu, and nef sequences were substi-
tuted with those derived from the pNL4-3 (vpr/vpu)78 and pLAI 
(nef)79 molecular clones, in order to introduce functional vpr, 
vpu, and nef genes, respectively. Jurkat cell supernatants 
were harvested at approximately 48 hours post- transfection, 
filtered (pore size, 0.45 µm) and stored at −80 °C until use. 
Viral titer was determined as 50% tissue culture infective 
doses (TCID50)/ml on C8166 cells by the Reed and Muench 
end point dilution method, as well as by measuring the RT 
activity assay, as previously described.80
HIV-1 NL4-3-ADA stocks were produced by calcium 
phosphate transfection of 2.5 × 106 293T cells with 15 µg of 
the infectious proviral plasmid, kindly provided by Heinrich 
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Göttlinger. The pNL4-3-ADA plasmid is a derivative of the 
HIV-1 pNL4-3, where the env sequence was replaced by the 
CCR5 coreceptor-using HIV-1 ADA envelope.81 The virus 
was collected from the culture supernatants on day 2 post-
transfection, filtered (pore size, 0.45 µm) and stored at −80 
°C. The HIV-1 NL4-3-ADA viral titer was determined by the 
RT assay.
Jurkat cells were seeded in a 12-well plate at the density 
of 1 × 106/well, and infected with HXBc2 Vpr+/Vpu+/Nef+ at an 
MOI of 0.1 TCID50/cell 4 days post-transduction. After 1 hour 
of incubation at 37 °C, the cultures were washed three times 
and cultured in RPMI 10% FBS medium. Virus replication 
was monitored by RT activity in cell-free culture supernatants 
at different days postinfection.
Phytohemagglutinin-activated human CD4+ T lympho-
cytes were seeded in a 24-well plate at two different densi-
ties (2.5 × 106/well and 1 × 106/well) and were challenged with 
equivalent RT units (10,000 cpm) of either HXBc2 Vpr+/Vpu+/
Nef+ or NL4-3-ADA, 24 hours after FACS sorting for EGFP 
expression. Infection was carried out as described above 
and cells were maintained in RPMI supplemented with 10% 
FBS, penicillin (100 U/ml), streptomycin (100 µg/ml), and IL-2 
(100 U/ml). The RT activity in culture supernatants was mea-
sured at different time points after infection.
Statistical analysis. Paired t-test was performed using Graph-
Pad Prism version 5.03 for Windows (GraphPad Software, 
San Diego, CA). Values of P less than or equal to 0.05, 0.01, 
and 0.001, were considered statistically significant (*, **, ***) 
compared to the respective control.
Supplementary material
Figure S1. Schematic representation of the reporter plas-
mids used for the luciferase assay.
Figure S2. Reduction of CCR5 surface expression on human 
primary macrophages transduced with the shCCR5 vectors.
Figure S3. Titer and transduction efficiency of the triple cas-
sette vectors.
Figure S4. Transduction efficiency of human primary CD4+ 
T lymphocytes transduced with the combinatorial vectors.
Figure S5. CCR5 surface expression on human primary 
CD4+ T lymphocytes.
Table S1. Sequences of the shRNAs cloned into the SIN len-
tiviral vector.
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